Jonathan Wright profile picture
315 464-8200

Jonathan Wright, MD

CURRENT APPOINTMENTS

Clinical Professor of Medicine

SPECIALTIES

Internal Medicine
Hematology
Oncology
Medical Oncology

LANGUAGES

English

PATIENT TYPE

Adults

RESEARCH PROGRAMS AND AFFILIATIONS

Medicine

RESEARCH INTERESTS

Gastrointestinal malignancies

EDUCATION

Fellowship: Boston City Hospital, 1985, Hematology/Oncology
Residency: University of Kansas Medical Center, Kansas City, KS, 1981, Internal Medicine
MD: University of Kansas School of Medicine, 1978

RESEARCH ABSTRACT

Selected References

Scott, L.C., Yao, J.C., Benson III, A.B., Thomas, A.L., Falk, S., Mena, R.R., Picus, J., Wright, J., Mulcahy, M.F., Ajani, J.A., Evans, T.R.J.  A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction and adenocarcinoma. Cancer Chemother Pharmacol. 63:363-370, 2009

Vahdat, Linda T., Pruitt, Brian, Fabian, Carol J., Rivera, Ragene R., Smith, David A., Tan-Chiu, Elizabeth, Wright, Jonathan, Tan, Antoinette R., DaCosta, Noshir A., Chuang, Ellen, Smith, John, O'Shaughnessy, Joyce, Shuster, Dale E., Meneses, Nicole L., Chandrawansa, Kumari, Fang, Fang, Cole, Patricia E., Ashworth, Simon, and Blum, Joanne L.  Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J Clin. Oncol 27:2954-2961, 2009

PUBLICATIONS

Link to PubMed (Opens new window. Close the PubMed window to return to this page.)